Core Viewpoint - The company Maipu Medical (301033.SZ) is planning its first asset restructuring post-IPO by acquiring 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. to expand its product offerings and enhance its global strategy [1][3]. Financial Performance - In 2024, Maipu Medical is projected to achieve revenue of 278 million yuan, a year-on-year increase of 20.61%, and a net profit of 78.85 million yuan, up 92.9% [1][8]. - The company's overseas revenue is expected to reach 56.69 million yuan, reflecting a 13.28% increase, accounting for 20.36% of total revenue [1][8]. Acquisition Details - The acquisition will be financed through a combination of share issuance and cash payment, with the controlling shareholder, Yuan Yuyu, participating in the fundraising [1][3]. - The target company, Yijie Medical, is currently unprofitable, with projected losses of 29.51 million yuan in 2023 and 26.16 million yuan in 2024 [1][4]. Strategic Rationale - Maipu Medical aims to leverage the acquisition to diversify its product matrix and enhance its market presence in the neurovascular intervention sector [6][7]. - The target company has 11 products on the market, including 8 Class III and 3 Class II medical devices, with 2 FDA registrations, which aligns with Maipu Medical's existing product lines [6][7]. Market Position - Maipu Medical is recognized as the only domestic company with a comprehensive range of neuro-surgical implantable medical devices, covering critical needs in cranial surgery [6]. - The company has established partnerships with nearly 1,000 distributors and its products are available in around 2,000 hospitals domestically, with a market presence in over 100 countries [8].

迈普医学（301033）6月5日晚间公告，公司拟通过发行股份及支付现金的方式向泽新医疗等10名交易对 方购买易介医疗100%股权。同时，公司拟向控股股东、实际控制人袁玉宇发行股份募集配套资金。 迈普医学是一家致力于结合人工合成材料特性，利用先进制造技术开发高性能植入医疗器械的高新技术 企业。目前，公司是国内神经外科领域唯一同时拥有人工硬脑(脊)膜补片、颅颌面修补及固定系统、可 吸收再生氧化纤维素、硬脑膜医用胶等植入医疗器械产品的企业，覆盖开颅手术所需要的关键植入医疗 器械。 易介医疗是一家为脑血管疾病治疗提供微创介入式整体解决方案的高新技术企业，主要从事神经内外科 领域的脑血管介入医疗器械的研发、生产和销售，为脑血管疾病治疗提供包括经桡动脉路径的通路解决 方案、取栓解决方案和狭窄解决方案等，囊括了主流的脑卒中介入手术方案。 截至预案签署日，本次交易标的公司的审计、评估工作尚未完成，本次交易标的资产的预估值及交易价 格尚未确定。 迈普医学表示，本次交易完成后，上市公司将进一步拓展产品品类，形成多元化的产品矩阵。上市公司 已与境内外近1000家经销商建立良好的合作关系，产品已进入国内近2000家医院，市场覆盖全球 ...

迈普医学（301033）(301033.SZ)筹划收购。 5月21日晚间，迈普医学发布公告，公司正在筹划发行股份及支付现金购买广州易介医疗科技有限公司 (简称"易介医疗")不低于51%的股权，并募集配套资金事项，此次交易预计构成重大资产重组，构成关 联交易。 一季度净利保持高速增长 资料显示，目前，迈普医学获得了10个中国医疗器械注册证及5个产品的MDR证书，市场已覆盖全球超 100个国家和地区，销售产品近130万件。 人工硬脑(脊)膜补片、颅颌面修补及固定系统是迈普医疗最主要的收入来源，分别占营业收入的55.88% 及28.69%。公司已与境内外近1000家经销商建立良好的合作关系，产品已进入国内近2000家医院。 近两年来，随着核心产品销量提升，迈普医学业绩持续增长，今年一季度，营业收入、净利润同比增速 分别达28.84%、61.68%。二级市场上，公司股价呈上扬走势，5月21日报收64.13元/股，较2024年2月低 点上涨近2倍。 拟收购易介医疗不低于51%股权 根据公告，迈普医学已与泽新医疗、易创享等主要交易对方签署了意向协议，收购完成后，上市公司将 成为易介医疗控股股东。本次交易的具体方案有待交易 ...